Retatrutide

Retatrutide (LY3437943) is a triple receptor agonist targeting GLP-1, GIP and glucagon receptors simultaneously. Currently under active Phase 3 clinical investigation for metabolic and cardiovascular research. >99% purity by HPLC. Lyophilised powder in a sealed vial, or pre-filled research pen.

20mg >99% Purity HPLC Verified Phase 3 Research

Format

Vial £115 / 20mg

Pen £125 / 20mg

Quantity

For in-vitro research use only. Not for human or veterinary use.

Specifications

Compound	Retatrutide (LY3437943)
Receptor Targets	GLP-1R, GIPR, GcgR
Purity	>99% (HPLC)
Form	Lyophilised powder (vial) / Pre-filled pen
Quantity	20mg
Storage	−20°C, protect from light